HOME >> BIOLOGY >> NEWS
Grant allows ASU archaeologist to study how environment influences evolution

ASU archaeologist Curtis Marean wants to learn more about modern human evolution by gaining a better understanding of the physical environment in which ancient peoples lived. Marean says relatively little is known about the environment that drove the evolution of modern humans.

To remedy that situation, Marean, who recently received a $2.5 million grant from the National Science Foundation, is bringing archaeologists together with scientists specializing in caves, ancient dune systems, chemical dating methods and other topics relevant to human evolution and ecological studies. The team will try to reconstruct the ancient ecological factors that likely influenced the evolution of Homo sapiens, and see what that might tell us about our species' future.

Marean is primarily concerned with an area of South Africa called Mossel Bay, known for its rich human fossil collection and considered by many scientists to be an important site in the history of human evolution. Marean believes a team-based approach will result in more fruitful research than the typically exclusive work done by specialists.

"This really is a transdisciplinary research project," Marean said. "Breaking down the boundaries between disciplines is very hard, but when you bring everyone together to interpret the same information, it gives you a lot more than if there was just that one specialist working on it."

Researchers agree that modern humans evolved in Africa, but little is known about the ancient ecology at the time. Scientists know that environment is one of the biggest influences that drives evolution, so reconstructing the environment from 400,000 years ago to 30,000 years ago might hold the key to understanding why humans evolved the way they did, Marean said.

"During glacial advances throughout the Pleistocene period (an era from 1.6 million years ago to 11,000 years ago), Africa became a lot drier and the Sahara Desert grew wider, creating isolated pocke
'"/>

Contact: Skip Derra
skip.derra@asu.edu
480-965-4823
Arizona State University
21-Dec-2005


Page: 1 2

Related biology news :

1. CSHL awarded Pre-College Science Education Grant by HHMI
2. Grant to Yale from Simons Foundation to explore genetic causes of autism
3. Granthams to fund Institute for Climate Change at Imperial College London
4. Grant aims to ignite inspiration and interest in science
5. EMBO Installation Grants help scientists get set up in Europe
6. Grant to UA makes Kartchner Caverns a Microbial Observatory
7. DoD awards $10.7 million Center of Excellence Grant to Fox Chases V. Craig Jordan
8. $14.6 million NIH Grant will build on macular degeneration findings
9. Stevens, N.J. Sea Grant to host coastal management workshop
10. Grants put ANU in bird flu fight frontline
11. Grant will promote Yale-India environmental ties

Post Your Comments:
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: